← Back to Search

Neuropeptide

Substance P for Type 1 Diabetes

Phase 1
Waitlist Available
Led By Etienne Sochett, MD
Research Sponsored by Vanilloid Genetics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 and 6 months
Awards & highlights

Study Summary

This trial looks at using a substance to treat type 1 diabetes by delivering it through the celiac artery.

Eligible Conditions
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Stage A Safety: Side effects reported for entire cohort
Secondary outcome measures
C-Peptide Levels (large cohort)
C-Peptide Levels (small cohort)
Other outcome measures
sP Longevity

Trial Design

4Treatment groups
Experimental Treatment
Group I: Substance P - 5nmol/kgExperimental Treatment1 Intervention
Substance P 5nmol/kg intra-celiac artery, single treatment
Group II: Substance P - 45nmol/kgExperimental Treatment1 Intervention
Substance P 45nmol/kg intra-celiac artery, single treatment
Group III: Substance P - 1nmol/kgExperimental Treatment1 Intervention
Substance P 1nmol/kg intra-celiac artery, single treatment
Group IV: Substance P - 15nmol/kgExperimental Treatment1 Intervention
Substance P 15nmol/kg intra-celiac artery, single treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Substance P
2021
N/A
~40

Find a Location

Who is running the clinical trial?

Vanilloid Genetics Inc.Lead Sponsor
Etienne Sochett, MDPrincipal InvestigatorHospital for Sick Children, Toronto Ontario
2 Previous Clinical Trials
26 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Hospital for Sick Children
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Neuropeptide Therapy of Recent Onset Type 1 Diabetes
2016. "Neuropeptide Therapy of Recent Onset Type 1 Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02820558.
All > Type 1 Diabetes
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top